Communiqués Toleranzia AB

Actions

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
0,598 ^SEK	-0,33 %		-2,61 %	+39,72 %

31/05	Toleranzia AB (publ) mène avec succès une étude d'innocuité du TOL2 dans des échantillons de sang de patients atteints de myasthénie grave	CI
20/05	Toleranzia AB publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Announcement from the 2024 Annual General Meeting of Toleranzia AB (publ)	19/06	AQ
Toleranzia AB conducts successful safety study of TOL2 in blood samples from patients with myasthenia gravis	31/05	AQ
Toleranzia : Annual General Meeting 2024 06 19 – Postal voting form	28/05	PU
Toleranzia : Annual General Meeting 2024 06 19 – Proxy form	28/05	PU
Toleranzia : Annual General Meeting 2024 06 19 – Annual Report 2023	28/05	PU
Toleranzia : Annual General Meeting 2024 06 19 – Auditor’s Report 2023	28/05	PU
Notice of Annual General Meeting in Toleranzia AB (publ)	20/05	AQ
Toleranzia AB: Interim report first quarter 2024	20/05	AQ
Toleranzia AB: Annual report for the financial year 2023	30/04	AQ
Toleranzia AB receives loan commitment of SEK 20 million	24/04	AQ
Toleranzia reports positive outcome from advisory meeting with the German Medicines Agency for the TOL2 development program	18/03	AQ
Toleranzia AB – Year-End Report 2023	23/02	AQ
Toleranzia successfully completes GLP toxicology study of TOL2	15/01	AQ
Toleranzia AB starts production of finished drug product for clinical studies	21/12	AQ
Toleranzia AB presents Nomination Committee	15/12	AQ
Toleranzia reports positive feedback from meeting with the Danish Medicines Agency	06/12	AQ
Toleranzia AB: Interim report third quarter 2023	27/10/23	AQ
Toleranzia appoints Thomas Pålsson as new Chief Financial Officer	16/10/23	AQ
Toleranzia starts toxicology study of its lead drug candidate TOL2	26/09/23	AQ
Toleranzia announces outcome in rights issue	15/09/23	AQ

Aucun résultat pour cette recherche